secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009928
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi renames to Metagenomi Therapeutics; hemophilia A program on track for IND in 2026
--------------------------------------------------------------------------------

- Name changed to Metagenomi Therapeutics, Inc. effective Jan 12, 2026; ticker MGX unchanged.
- Lead program MGX-001: pre-IND meeting completed; IND/CTA on track for Q4 2026.
- Preclinical data showed curative FVIII activity in NHPs with no off-target editing.
- Cash runway extended to Q4 2027 following strategic pipeline prioritization.
- Jian Irish appointed CEO as part of strategic evolution toward in vivo gene editing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526009928/0001193125-26-009928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526009928/mgx-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer